PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Health Decisions

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Health Decisions CEO Explores Adaptive Monitoring Techniques for Late-Stage Clinical Studies at DIA - Dr. Michael Rosenberg will describe how fast access to metrics, flexible processes, and automated technology enable study monitors to increase efficiency
Health Decisions CEO Explores Adaptive Monitoring Techniques for Late-Stage Clinical Studies at DIA

 

NewswireToday - /newswire/ - Durham, NC, United States, 2010/06/08 - Dr. Michael Rosenberg will describe how fast access to metrics, flexible processes, and automated technology enable study monitors to increase efficiency.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Health Decisions (Booth 929), a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, announces that CEO Michael Rosenberg, MD, MPH will join a panel June 14 at the DIA Annual Meeting in Washington, DC. "Centralized Monitoring: When Does It Make Sense?" will focus on the advantages and requirements of monitoring programs that balance the needs of sponsor companies and investigative sites in phase IIIb to postmarket clinical studies.

According to Dr. Rosenberg, a centralized monitoring system should be based on the same general principle as adaptive design, a hot topic in the industry. Adaptive monitoring involves capturing and presenting site performance metrics to study monitors in near-real time, allowing monitors to make mid-course adjustments to study operations based on current information. This enables decision-makers to optimize site activity on a rolling and continuous basis for dramatic aggregate time- and cost-savings.

“Applied to site management, adaptive methodology empowers monitors to be more than just box-checkers,” said Dr. Rosenberg. “Each team member has the training and tools to improve site performance. When the whole team is thinking critically about the overall health of the study, you get better quality data and faster execution at every stage, from start-up and enrollment through database lock and submission."

"Centralized Monitoring: When Does It Make Sense?" will explore monitoring solutions that provide economies of scale, allocate resources efficiently, optimize every aspect of operations, and alleviate sponsors’ concerns about budget and timelines. Such solutions include:

· Need-based monitoring visits: how to reliably and efficiently determine when to dispatch monitors to sites;
· Managing based on performance metrics: which metrics to look for, how to track and report trends, and what actions to take when opportunities to improve efficiency are indicated;
· Automated data capture and processing tools;
· Electronic data as source documents.

The session will be chaired by Ramita Tandon, MPH, MSc, senior director, project management, per-approval services (PACE) at PAREXEL International. The session is part of the Clinical Research and Development/Clinical Supplies (CR/CS) track, and takes place June 14 from 3:30 – 5:00 p.m. EDT in Room 145B.

About Health Decisions
Health Decisions (HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development—a strategic combination of adaptive design and adaptive operations—Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.

Health Decisions is headquartered in Durham, NC, with over twenty years of experience helping sponsors achieve success in Phase I-IV trials across all major therapy areas. For more information, please visit the company's website at the link accompanying this press release.

About the DIA Annual Meeting
Hosted by the Drug Information Association, the DIA 46th Annual Meeting takes place June 13 – 17, 2010 at the Walter E. Washington Convention Center, Washington, DC. The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, best-value, global, multidisciplinary event. To learn more, visit DIA online.

About the Drug Information Association (DIA)
DIA is a neutral, global, professional, member-driven association of nearly 18,000 industry, academia, and regulatory professionals involved in the discovery, development, and life cycle management of pharmaceuticals, medical devices, and related products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well-being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Health Decisions

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Health Decisions CEO Explores Adaptive Monitoring Techniques for Late-Stage Clinical Studies at DIA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Katie Hendrick - HealthDec.com 
919-967-1111 x116 khendrick[.]HealthDec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Health Decisions securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Health Decisions / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)